U.S. markets close in 4 hours 42 minutes
  • S&P 500

    3,769.67
    -13.61 (-0.36%)
     
  • Dow 30

    30,155.29
    -118.58 (-0.39%)
     
  • Nasdaq

    11,123.94
    -24.70 (-0.22%)
     
  • Russell 2000

    1,756.99
    -5.70 (-0.32%)
     
  • Crude Oil

    88.52
    +0.76 (+0.87%)
     
  • Gold

    1,719.90
    -0.90 (-0.05%)
     
  • Silver

    20.55
    +0.01 (+0.03%)
     
  • EUR/USD

    0.9827
    -0.0057 (-0.58%)
     
  • 10-Yr Bond

    3.8260
    +0.0670 (+1.78%)
     
  • GBP/USD

    1.1175
    -0.0146 (-1.29%)
     
  • USD/JPY

    144.8210
    +0.2110 (+0.15%)
     
  • BTC-USD

    20,031.85
    +138.05 (+0.69%)
     
  • CMC Crypto 200

    456.58
    -6.54 (-1.41%)
     
  • FTSE 100

    6,995.41
    -57.21 (-0.81%)
     
  • Nikkei 225

    27,311.30
    +190.77 (+0.70%)
     

Seer to Participate in the Morgan Stanley Global Healthcare Conference

·1 min read
Seer, Inc.
Seer, Inc.

REDWOOD CITY, Calif., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced that the company will be participating in the upcoming Morgan Stanley Global Healthcare Conference in New York City, New York.

Seer’s management is scheduled to participate in a fireside chat on Tuesday, September 13th at 8:35 a.m. Eastern Time / 5:35 a.m. Pacific Time. A live webcast of the session will be available on the Investor section of Seer’s website at investor.seer.bio. An archived replay will be available on the company’s website following the conference.

About Seer
Seer™ is a life sciences company developing transformative products that open a new gateway to the proteome. Seer’s Proteograph™ Product Suite is an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation and software to perform deep, unbiased proteomic analysis at scale in a matter of hours. Seer designed the Proteograph workflow to be efficient and easy to use, leveraging widely adopted laboratory instrumentation to provide a decentralized solution that can be incorporated by nearly any lab. Seer’s Proteograph Product Suite is for research use only and is not intended for diagnostic procedures. For more information, please visit www.seer.bio.

Investor Contact
Carrie Mendivil
investor@seer.bio

Media Contact
Karen Possemato
pr@seer.bio